Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience
Abstract Background A fixed 8-cycle oxaliplatin and capecitabine (XELOX) regimen has been the standard adjuvant therapy for patients with stage III colon cancer. However, completing the full-cycle of oxaliplatin is often associated with severe neurotoxicity. To spare patients from the toxic effects,...
Main Authors: | Jianhong Peng, Weihao Li, Rongxin Zhang, Junzhong Lin, Jinghua Tang, Yongshan Wen, Zhenhai Lu, Xiaojun Wu, Zhizhong Pan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-10-01
|
Series: | Cancer Communications |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40880-019-0400-x |
Similar Items
-
Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
by: Yu S, et al.
Published: (2020-10-01) -
Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study
by: Tsunekazu Mizushima, et al.
Published: (2019-09-01) -
Feasibility Study of a Modified XELOX Adjuvant Chemotherapy for High-Recurrence Risk Patients With Operated Stage III Colon Cancer
by: Jianhong Peng, et al.
Published: (2020-09-01) -
Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
by: Yuanyuan Yu, et al.
Published: (2021-05-01) -
Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX
by: Xin Yin, et al.
Published: (2020-12-01)